Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS P STERN

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1083639439
CMS profile
185337
Location
HUNTERSVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$14,332.05

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS P STERN

NPI 1083639439 · CMS profile ID 185337

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

HUNTERSVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS P STERN, NPI 1083639439, CMS profile ID 185337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). THOMAS P STERN, NPI 1083639439, CMS profile ID 185337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
THOMAS P STERN, NPI 1083639439, CMS profile ID 185337, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $14,332.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Avadel CNS Pharmaceuticals, LLC $13.7507/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208542542 CMS
Avadel CNS Pharmaceuticals, LLC $13.7507/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208542540 CMS
Azurity Pharmaceuticals, Inc. $18.3407/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242679707 CMS
JAZZ PHARMACEUTICALS INC. $13.5707/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234345527 CMS
GlaxoSmithKline, LLC. $6.8606/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191002376 CMS
JAZZ PHARMACEUTICALS INC. $11.0306/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234346373 CMS
Avadel CNS Pharmaceuticals, LLC $545.0006/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208542538 CMS
Axsome Therapeutics, Inc. $31.7306/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235739377 CMS
JAZZ PHARMACEUTICALS INC. $14.0406/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234345121 CMS
Fisher & Paykel Healthcare Inc $16.4005/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244153647 CMS
Avadel CNS Pharmaceuticals, LLC $23.9405/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208542536 CMS
JAZZ PHARMACEUTICALS INC. $11.6305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234346207 CMS
JAZZ PHARMACEUTICALS INC. $13.2905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234345641 CMS
JAZZ PHARMACEUTICALS INC. $14.1505/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234345055 CMS
JAZZ PHARMACEUTICALS INC. $10.6004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234346623 CMS
JAZZ PHARMACEUTICALS INC. $8.8504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234347107 CMS
GlaxoSmithKline, LLC. $4.5804/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191805830 CMS
JAZZ PHARMACEUTICALS INC. $19.5704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234337547 CMS
GlaxoSmithKline, LLC. $8.7203/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190899167 CMS
GlaxoSmithKline, LLC. $16.8503/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191574421 CMS
GlaxoSmithKline, LLC. $4.2803/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191121139 CMS
AstraZeneca Pharmaceuticals LP $24.8603/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214780725 CMS
GlaxoSmithKline, LLC. $15.9302/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191334186 CMS
GlaxoSmithKline, LLC. $4.6102/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190655746 CMS
GlaxoSmithKline, LLC. $3.9202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191066796 CMS
Inspire Medical Systems, Inc. $26.0102/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251511680 CMS
JAZZ PHARMACEUTICALS INC. $16.7502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234341892 CMS
JAZZ PHARMACEUTICALS INC. $0.8902/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234349236 CMS
AstraZeneca Pharmaceuticals LP $15.3802/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214776451 CMS
GlaxoSmithKline, LLC. $8.0102/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191650909 CMS
JAZZ PHARMACEUTICALS INC. $150.0001/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234303559 CMS
JAZZ PHARMACEUTICALS INC. $20.2801/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234336407 CMS
GlaxoSmithKline, LLC. $4.1701/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190740572 CMS
GlaxoSmithKline, LLC. $10.4001/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190726658 CMS
GlaxoSmithKline, LLC. $110.3901/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191366190 CMS
JAZZ PHARMACEUTICALS INC. $10.2201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234346721 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $661.89 29
PY2020 $1,480.04 18
PY2021 $532.18 24
PY2022 $886.40 35
PY2023 $9,505.44 48
PY2024 $3,717.98 25
PY2025 $14,332.05 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,661,665.19 468
PY2024 Principal investigator $1,894,768.84 859
PY2023 Principal investigator $926,087.97 207
PY2022 Principal investigator $280,982.24 71
PY2021 Principal investigator $90,582.08 25
PY2020 Principal investigator $101,650.81 110
PY2019 Principal investigator $165,124.47 127

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

468 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $119,238.40 12/31/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554245
Principal investigator 1 Alkermes, Inc. $7,817.00 12/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613125
Principal investigator 1 Alkermes, Inc. $5,741.00 12/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614190
Principal investigator 1 Alkermes, Inc. $2,538.00 12/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618993
Principal investigator 1 Alkermes, Inc. $70.00 12/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617597
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636313
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636315
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636317
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.24 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736925
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736927
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736929
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736931
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.84 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736933
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $238.56 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736935
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.50 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736937
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.56 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736939
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $237.40 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736941
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.60 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736947
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.30 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736949
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $93.50 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736951
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32.08 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736953
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736955
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736957
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.31 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736959
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.60 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736961
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $17.80 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736963
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736965
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736967
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $20.80 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736969
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14.26 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736971
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736973
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.75 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736975
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.34 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736977
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736979
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $33.00 11/24/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736981
Principal investigator 1 Alkermes, Inc. $2,359.00 11/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624566
Principal investigator 1 Alkermes, Inc. $5,629.00 11/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626088
Principal investigator 1 Alkermes, Inc. $314.00 11/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613980
Principal investigator 1 Alkermes, Inc. $2,367.00 11/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614865
Principal investigator 1 Alkermes, Inc. $2,164.00 11/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619471
Principal investigator 1 Alkermes, Inc. $41.04 11/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617351
Principal investigator 1 Alkermes, Inc. $27.36 11/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620994
Principal investigator 1 Alkermes, Inc. $58.23 11/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626904
Principal investigator 1 PFIZER INC. $18,950.00 11/04/2025 Non-covered Recipient Entity
Stern Research Partners
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228737340
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,027.04 11/03/2025 Non-covered Recipient Entity
STERN RESEARCH PARTNERS LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223287851
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636307
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636309
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,870.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744429
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,632.15 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744431
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,868.25 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744435
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $456.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744437
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70,645.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744439
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,852.20 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744443
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,953.50 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744445
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $52,458.30 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744447
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $104,170.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744451
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,820.70 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744453
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,600.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744455
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $15,120.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744459
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32,400.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744461
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,784.80 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744463
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,000.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744465
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $972.00 10/27/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744467
Principal investigator 1 Alkermes, Inc. $314.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613321
Principal investigator 1 Alkermes, Inc. $805.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614188
Principal investigator 1 Alkermes, Inc. $3,097.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614625
Principal investigator 1 Alkermes, Inc. $2,472.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617401
Principal investigator 1 Alkermes, Inc. $5,741.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618037
Principal investigator 1 Alkermes, Inc. $4,839.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621474
Principal investigator 1 Alkermes, Inc. $7,665.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623694
Principal investigator 1 Alkermes, Inc. $2,451.00 10/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625215
Principal investigator 1 GENZYME CORPORATION $3,384.00 10/20/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226088982
Principal investigator 1 Alkermes, Inc. $1,300.00 10/15/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622333
Principal investigator 1 Alkermes, Inc. $2,000.00 10/15/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623490
Principal investigator 1 Alkermes, Inc. $10,000.00 10/15/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625465
Principal investigator 1 Genentech, Inc. $1,359.00 10/15/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211570084
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 10/13/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744433
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 10/13/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744441
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,000.00 10/13/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744449
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/13/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744457
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 10/13/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744469
Principal investigator 1 PFIZER INC. $4,425.40 10/11/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINEHUNTERSVILLE
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228728047
Principal investigator 1 Alkermes, Inc. $312.00 10/08/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615661
Principal investigator 1 Alkermes, Inc. $5,521.00 10/08/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619725
Principal investigator 1 Alkermes, Inc. $552.10 10/08/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625922
Principal investigator 1 Alkermes, Inc. $1,342.00 10/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613127
Principal investigator 1 Alkermes, Inc. $314.00 10/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621476
Principal investigator 1 Alkermes, Inc. $314.00 10/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624806
Principal investigator 1 PFIZER INC. $1,339.39 10/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINEHUNTERSVILLE
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228719713
Principal investigator 1 Alkermes, Inc. $524.80 10/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617127
Principal investigator 1 Alkermes, Inc. $191.52 10/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617735
Principal investigator 1 Alkermes, Inc. $37.90 10/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618917
Principal investigator 1 Alkermes, Inc. $58.23 10/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619419
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636301
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636303
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636305
Principal investigator 1 Alkermes, Inc. $7,817.00 09/25/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617625
Principal investigator 1 Alkermes, Inc. $2,359.00 09/25/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625055
Principal investigator 1 Alkermes, Inc. $948.00 09/25/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626774
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 09/23/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192142264
Principal investigator 1 Alkermes, Inc. $2,733.00 09/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615955
Principal investigator 1 Alkermes, Inc. $2,733.00 09/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617233
Principal investigator 1 Alkermes, Inc. $2,733.00 09/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623938
Principal investigator 1 Alkermes, Inc. $2,733.00 09/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625059
Principal investigator 1 Alkermes, Inc. $2,733.00 09/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626146
Principal investigator 1 SANOFI US SERVICES INC. $20,000.00 09/15/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226088976
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615323
Principal investigator 1 Alkermes, Inc. $119.25 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615731
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619545
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620241
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623532
Principal investigator 1 Alkermes, Inc. $112.80 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624622
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625289
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,200.00 09/03/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744411
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 09/03/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744417
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100,845.67 09/03/2025 Non-covered Recipient Entity
Stern Research Partners
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233744419
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,390.00 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,780.00 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,780.00 09/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284935
Principal investigator 1 Verona Pharma, Inc. $9,500.00 09/03/2025 Non-covered Recipient Entity
STERN RESEARCH PARTNERS LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891339
Principal investigator 1 Verona Pharma, Inc. $1,800.00 09/03/2025 Non-covered Recipient Entity
STERN RESEARCH PARTNERS LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891341
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636283
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636285
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636287
Principal investigator 1 AstraZeneca Pharmaceuticals LP $174.50 08/27/2025 Non-covered Recipient Entity
STERN RESEARCH PARTNERS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185541360
Principal investigator 1 Alkermes, Inc. $2,451.00 08/20/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613551
Principal investigator 1 Alkermes, Inc. $5,629.00 08/20/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617021
Principal investigator 1 Alkermes, Inc. $314.00 08/20/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624848
Principal investigator 1 Alkermes, Inc. $805.00 08/20/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625527
Principal investigator 1 SANOFI US SERVICES INC. $5,156.20 08/18/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226142841
Principal investigator 1 GlaxoSmithKline, LLC. $8,901.30 08/14/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192142280
Principal investigator 1 GlaxoSmithKline, LLC. $3,048.98 08/14/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192180419
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615919
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 08/07/2025 Non-covered Recipient Entity
INTERSPOND LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192180405
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636267
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636269
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636271
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636273
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636275
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636277
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636279
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 08/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,540.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,208.24 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283451
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283455
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283457
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,150.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,170.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,780.00 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $244.90 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,468.71 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,748.27 08/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283621
Principal investigator 1 GlaxoSmithKline, LLC. $18,748.60 07/31/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192142259
Principal investigator 1 GlaxoSmithKline, LLC. $37,468.75 07/31/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192142273
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,819.00 07/29/2025 Non-covered Recipient Entity
STERN RESEARCH PARTNERS
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185541354
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636289
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636291
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636293
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636295
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636297
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/28/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636299
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $146.93 07/25/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744413
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/25/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744415
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,070.00 07/25/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744421
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 07/25/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744425
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 07/25/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744427
Principal investigator 1 Alkermes, Inc. $3,097.00 07/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615951
Principal investigator 1 Alkermes, Inc. $7,665.00 07/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618091
Principal investigator 1 Alkermes, Inc. $2,472.00 07/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624612
Principal investigator 1 Alkermes, Inc. $4,839.00 07/23/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625057
Principal investigator 1 Alkermes, Inc. $1,196.53 07/21/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613341
Principal investigator 1 Alkermes, Inc. $1,196.53 07/21/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618299
Principal investigator 1 SANOFI US SERVICES INC. $9,000.00 07/21/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226142818
Principal investigator 1 Alkermes, Inc. $1,196.53 07/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613143
Principal investigator 1 Alkermes, Inc. $312.00 07/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618093
Principal investigator 1 Alkermes, Inc. $947.00 07/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618095
Principal investigator 1 Alkermes, Inc. $3,751.00 07/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626350
Principal investigator 1 GENZYME CORPORATION $1,299.00 07/14/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226088960
Principal investigator 1 SANOFI US SERVICES INC. $5,156.20 07/14/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226142815
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,465.39 07/11/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $32,527.40 07/11/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223282550
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,027.04 07/11/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223282560
Principal investigator 1 GlaxoSmithKline, LLC. $250,222.50 07/04/2025 Non-covered Recipient Entity
RESEARCH CAROLINA
A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, No dispute reported 06/30/2026 1192142269
Principal investigator 1 Alkermes, Inc. $8.04 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613379
Principal investigator 1 Alkermes, Inc. $115.65 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614022
Principal investigator 1 Alkermes, Inc. $64.25 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614913
Principal investigator 1 Alkermes, Inc. $111.36 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617845
Principal investigator 1 Alkermes, Inc. $2.61 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618109
Principal investigator 1 Alkermes, Inc. $56.10 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618111
Principal investigator 1 Alkermes, Inc. $36.40 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619543
Principal investigator 1 Alkermes, Inc. $3.50 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620035
Principal investigator 1 Alkermes, Inc. $19.26 07/02/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620037
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636261
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636263
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636265
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612895
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613189
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613595
Principal investigator 1 Alkermes, Inc. $1.96 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613768
Principal investigator 1 Alkermes, Inc. $23.52 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614000
Principal investigator 1 Alkermes, Inc. $449.75 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614284
Principal investigator 1 Alkermes, Inc. $3.50 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614288
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614422
Principal investigator 1 Alkermes, Inc. $4.27 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614639
Principal investigator 1 Alkermes, Inc. $0.87 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614655
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614869
Principal investigator 1 Alkermes, Inc. $65.45 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614875
Principal investigator 1 Alkermes, Inc. $3.50 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614957
Principal investigator 1 Alkermes, Inc. $4.27 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615099
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615341
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615673
Principal investigator 1 Alkermes, Inc. $25.48 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615709
Principal investigator 1 Alkermes, Inc. $141.35 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615755
Principal investigator 1 Alkermes, Inc. $13.72 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616141
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616353
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616455
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616625
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616757
Principal investigator 1 Alkermes, Inc. $10.90 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617043
Principal investigator 1 Alkermes, Inc. $89.95 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617057
Principal investigator 1 Alkermes, Inc. $2.14 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617085
Principal investigator 1 Alkermes, Inc. $25.70 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617269
Principal investigator 1 Alkermes, Inc. $3.15 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617457
Principal investigator 1 Alkermes, Inc. $145.60 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617465
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617671
Principal investigator 1 Alkermes, Inc. $4.55 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617673
Principal investigator 1 Alkermes, Inc. $28.14 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618567
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618625
Principal investigator 1 Alkermes, Inc. $2.45 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618627
Principal investigator 1 Alkermes, Inc. $12.84 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618643
Principal investigator 1 Alkermes, Inc. $37.12 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618855
Principal investigator 1 Alkermes, Inc. $4.20 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619105
Principal investigator 1 Alkermes, Inc. $171.75 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619113
Principal investigator 1 Alkermes, Inc. $17.12 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619331
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619335
Principal investigator 1 Alkermes, Inc. $19.60 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619341
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619577
Principal investigator 1 Alkermes, Inc. $17.64 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619777
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619829
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620069
Principal investigator 1 Alkermes, Inc. $4.35 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620211
Principal investigator 1 Alkermes, Inc. $17.12 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620295
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620451
Principal investigator 1 Alkermes, Inc. $185.60 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620922
Principal investigator 1 Alkermes, Inc. $0.80 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621140
Principal investigator 1 Alkermes, Inc. $11.76 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621152
Principal investigator 1 Alkermes, Inc. $58.80 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621160
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621554
Principal investigator 1 Alkermes, Inc. $0.35 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621748
Principal investigator 1 Alkermes, Inc. $182.00 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621983
Principal investigator 1 Alkermes, Inc. $182.00 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621985
Principal investigator 1 Alkermes, Inc. $38.47 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622135
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622755
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622854
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623090
Principal investigator 1 Alkermes, Inc. $12.85 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623092
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623504
Principal investigator 1 Alkermes, Inc. $10.50 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623572
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623574
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623778
Principal investigator 1 Alkermes, Inc. $46.75 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623916
Principal investigator 1 Alkermes, Inc. $40.20 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623928
Principal investigator 1 Alkermes, Inc. $74.90 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624026
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624214
Principal investigator 1 Alkermes, Inc. $46.75 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624394
Principal investigator 1 Alkermes, Inc. $11.76 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624402
Principal investigator 1 Alkermes, Inc. $17.12 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624464
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624820
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624885
Principal investigator 1 Alkermes, Inc. $46.75 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625239
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625467
Principal investigator 1 Alkermes, Inc. $0.70 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625798
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626100
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626114
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626116
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626196
Principal investigator 1 Alkermes, Inc. $19.60 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626212
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626336
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626604
Principal investigator 1 Alkermes, Inc. $38.55 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626606
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626740
Principal investigator 1 Alkermes, Inc. $38.47 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626744
Principal investigator 1 Alkermes, Inc. $3.92 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626772
Principal investigator 1 Alkermes, Inc. $5.45 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626824
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626866
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736917
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736919
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736921
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.48 06/11/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736923
Principal investigator 1 Alkermes, Inc. $72.00 06/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624724
Principal investigator 1 Alkermes, Inc. $51.80 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614132
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614457
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614459
Principal investigator 1 Alkermes, Inc. $48.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614801
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615481
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616189
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616611
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621134
Principal investigator 1 Alkermes, Inc. $64.94 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621402
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625559
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626186
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220636259
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744387
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744389
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,327.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744391
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,067.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744393
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,000.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744395
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $205.20 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744397
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,027.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744399
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744401
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,500.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744403
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744405
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,740.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744407
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,986.00 05/23/2025 Non-covered Recipient Entity
Stern Research Partners
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233744409
Principal investigator 1 Alkermes, Inc. $495.41 05/21/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613403
Principal investigator 1 GENZYME CORPORATION $1,787.00 05/21/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226085493
Principal investigator 1 Alkermes, Inc. $2,551.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613449
Principal investigator 1 Alkermes, Inc. $802.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614120
Principal investigator 1 Alkermes, Inc. $2,551.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614787
Principal investigator 1 Alkermes, Inc. $2,297.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618451
Principal investigator 1 Alkermes, Inc. $1,783.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619879
Principal investigator 1 Alkermes, Inc. $312.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620564
Principal investigator 1 Alkermes, Inc. $2,309.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620980
Principal investigator 1 Alkermes, Inc. $2,551.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622487
Principal investigator 1 Alkermes, Inc. $312.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623812
Principal investigator 1 Alkermes, Inc. $3,751.00 05/19/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625629
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614775
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615005
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618187
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619147
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621184
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622479
Principal investigator 1 Alkermes, Inc. $947.00 05/16/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622892
Principal investigator 1 GENZYME CORPORATION $1,787.00 05/12/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226085489
Principal investigator 1 Genentech, Inc. $7,155.00 05/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211570081
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,362.24 04/23/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185541356
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613317
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626966
Principal investigator 1 SANOFI US SERVICES INC. $15,378.60 04/11/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226085440
Principal investigator 1 SANOFI US SERVICES INC. $5,310.20 04/11/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226085444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,496.00 04/11/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223277888
Principal investigator 1 Alkermes, Inc. $61.60 04/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613199
Principal investigator 1 Alkermes, Inc. $77.10 04/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616841
Principal investigator 1 SANOFI US SERVICES INC. $15,378.60 04/02/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226142708
Principal investigator 1 SANOFI US SERVICES INC. $5,310.20 04/02/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226142714
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,033.88 03/28/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185541362
Principal investigator 1 GENZYME CORPORATION $1,299.00 03/24/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226085423
Principal investigator 1 Alkermes, Inc. $1,196.53 03/20/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626330
Principal investigator 1 GENZYME CORPORATION $19,899.00 03/06/2025 Non-covered Recipient Entity
Stern Research Partners Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226085419
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613962
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615421
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616075
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622976
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,496.00 02/21/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223275437
Principal investigator 1 GENZYME CORPORATION $1,299.00 02/18/2025 Non-covered Recipient Entity
Advanced Respiratory And Sleep Medicine, Pllc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226142731
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614547
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615819
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618671
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619363
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619365
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619619
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619623
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620968
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622673
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622906
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623146
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623810
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624298
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625834
Principal investigator 1 Alkermes, Inc. $6.40 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613948
Principal investigator 1 Alkermes, Inc. $2,479.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614517
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614605
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614835
Principal investigator 1 Alkermes, Inc. $2,309.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615349
Principal investigator 1 Alkermes, Inc. $12.85 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615859
Principal investigator 1 Alkermes, Inc. $12.85 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615863
Principal investigator 1 Alkermes, Inc. $2,297.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616223
Principal investigator 1 Alkermes, Inc. $855.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616651
Principal investigator 1 Alkermes, Inc. $52.80 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616965
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617165
Principal investigator 1 Alkermes, Inc. $167.05 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617559
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618025
Principal investigator 1 Alkermes, Inc. $44.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618963
Principal investigator 1 Alkermes, Inc. $25.65 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619721
Principal investigator 1 Alkermes, Inc. $38.55 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620604
Principal investigator 1 Alkermes, Inc. $9.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621236
Principal investigator 1 Alkermes, Inc. $64.25 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621440
Principal investigator 1 Alkermes, Inc. $2,297.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621562
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621652
Principal investigator 1 Alkermes, Inc. $44.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625203
Principal investigator 1 Alkermes, Inc. $89.95 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625423
Principal investigator 1 Alkermes, Inc. $312.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626218
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626494
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626952
Principal investigator 1 Alkermes, Inc. $44.00 02/12/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626958
Principal investigator 1 Alkermes, Inc. $82.08 02/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616333
Principal investigator 1 Alkermes, Inc. $77.64 02/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618537
Principal investigator 1 Alkermes, Inc. $228.53 02/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623224
Principal investigator 1 Alkermes, Inc. $52.48 02/10/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624560
Principal investigator 1 Genentech, Inc. $8,544.00 02/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211570073
Principal investigator 1 Genentech, Inc. $6,679.00 02/07/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211570077
Principal investigator 1 GlaxoSmithKline, LLC. $873.00 02/07/2025 Non-covered Recipient Entity
INTERSPOND LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192180399
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,176.12 02/03/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736879
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736854
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736862
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736881
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736895
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,008.04 01/29/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185541358
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,500.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,986.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736876
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736887
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736899
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $993.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736901
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,327.00 01/22/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736913
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616003
Principal investigator 1 Alkermes, Inc. $855.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618423
Principal investigator 1 Alkermes, Inc. $802.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618425
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618885
Principal investigator 1 Alkermes, Inc. $7,740.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618889
Principal investigator 1 Alkermes, Inc. $855.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619135
Principal investigator 1 Alkermes, Inc. $2,479.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619847
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622229
Principal investigator 1 Alkermes, Inc. $2,479.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622876
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622878
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623384
Principal investigator 1 Alkermes, Inc. $5,521.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624036
Principal investigator 1 Alkermes, Inc. $2,297.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624680
Principal investigator 1 Alkermes, Inc. $312.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625840
Principal investigator 1 Alkermes, Inc. $2,297.00 01/17/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626404
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $685.93 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736844
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,306.80 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736846
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $831.60 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736848
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,141.45 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11,029.50 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736852
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736856
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $341.55 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736858
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736864
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736866
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736868
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736870
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736872
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,906.20 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736874
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736885
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $699.30 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736889
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736891
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736893
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736897
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $831.60 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736903
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736905
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736907
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.35 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736909
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11,029.50 01/17/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233736915
Principal investigator 1 GlaxoSmithKline, LLC. $2,490.18 01/13/2025 Non-covered Recipient Entity
INTERSPOND LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192180410
Principal investigator 1 GlaxoSmithKline, LLC. $10,852.57 01/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192180394
Principal investigator 1 GlaxoSmithKline, LLC. $2,965.00 01/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192180402
Principal investigator 1 GlaxoSmithKline, LLC. $4,980.00 01/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192180414
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.15 01/06/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736860
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.15 01/06/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736883
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.90 01/06/2025 Non-covered Recipient Entity
Advanced Respiratory and Sleep Medicine, PLLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233736911
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627122
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627198
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627268